阿卡迪亚 2026年季度报告

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ Total shares of registrant’s common stock outstanding as of the close of business on April 29, 2026: PART I. FINANCIAL INFORMATION PART II. OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 5.Other InformationItem 6.ExhibitsSIGNATURES ACADIA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Net income ACADIA PHARMACEUTICALS INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. Organization and Business Acadia Pharmaceuticals Inc. (the Company), based in San Diego, California, is a biopharmaceutical company focused onturning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease In April 2016, the U.S. Food and Drug Administration (FDA) approved the Company’s first drug, NUPLAZID®(pimavanserin), for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZIDbecame available for prescription in the United States in May 2016. In March 2023, the FDA approved the Company’s second drug, DAYBUE®(trofinetide), for the treatment of Rett syndrome.DAYBUE became available for prescription in the United States in April 2023. In October 2024, Health Canada granted marketing authorization of DAYBUE®(trofinetide) for the treatment of Rettsyndrome in adult and pediatric patients 2 years of age and older. In December 2025, the FDA approved DAYBUE® the treatment of Rett syndrome in adult and pediatric patients 2 years and older. DAYBUE STIX was available on a limited basisstarting in the first quarter of 2026 followed by a broader launch early in the second quarter of 2026. In December 2025, the Ministry of Health in Israel approved DAYBUE®(trofinetide) for the treatment of Rett syndrome inadults and pediatric patients 2 years of age and older and weighing at least 9 kg. 2. Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company should be read in conjunctionwith the audited financial statements and notes thereto as of and for the year ended December 31, 2025 included in the Company’sAnnual Report on Form 10-K (Annual Report) filed with the Securities and Exchange Commission (the SEC). The accompanyingunaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generallyaccepted in the United States (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q andArticle 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying unaudited condensed consolidatedfinancial statements do not include all of the information and notes required by GAAP for complete financial statements. In the Risk and Uncertainties Global economic and business activities continue to face widespread macroeconomic uncertainties, including inflation andmonetary supply shifts, recession risks, volatility and disruptions in global credit and financial markets, potential disruptions fromgeopolitical and military conflicts and related sanctions and tariffs and trade tensions. The Company continues to actively monitorthe impact of these macroeconomic factors on its financial condition, liquidity, operations and workforce. The extent of the impactof these factors on the Company’s operational and financial performance, including its ability to execute its business strategies and Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with a maturity date at the date of purchase of three months or less to be The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the unaudit